RxDoctor Payments Data

Naveen Sablani, MD

Cardiovascular Disease · Plantation, FLNPI 1326482092

Payments from drug & device makers

$590in general payments, 2019–2025

Across 12 payments — averaging $49.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$362
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$133
  • E.r. Squibb & Sons, L.L.C.$47
  • Johnson & Johnson$18
  • Novartis$15
  • Boston Scientific$15

What the payments were for

  • Food & beverage$590100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$590 in reported general payments places this provider in the 15th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$130,411
Medicare patients
199
Services billed
902

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban61$75,187
XareltoRivaroxaban38$42,785
EntrestoSacubitril/Valsartan16$15,128
Metoprolol Succinate90$1,630
Atorvastatin Calcium76$967
Ezetimibe38$752
Rosuvastatin Calcium38$610
Lisinopril50$551
Isosorbide Mononitrate ErIsosorbide Mononitrate23$519
Amlodipine Besylate40$377
Carvedilol45$350
Furosemide64$350
Losartan Potassium38$311
Amiodarone Hcl15$300
Metoprolol Tartrate35$295

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$18$42,78538 claims
NovartisEntresto$15$15,12816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Plantation

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →